Last updated: 11/07/2018 12:04:50
COMORBIDITIES ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE MIDDLE EAST: ANALYSIS FROM THE BREATHE STUDY
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: COMORBIDITIES ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE MIDDLE EAST: ANALYSIS FROM THE BREATHE STUDY
Trial description: COMORBIDITIES ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE MIDDLE EAST: ANALYSIS FROM THE BREATHE STUDY
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Bassam MAHBOUB, Ashraf ALZAABI, Mohammed Nizam IQBAL, Hocine SALHI, Aïcha LAHLOU, Luqman TARIQ and Abdelkader EL HASNAOUI. Comorbidities associated with COPD in the Middle East and North Africa region: association with severity and exacerbations. Int J Chron Obstruct Pulmon Dis. 2016;11(1):273-280
Medical condition
Pulmonary Disease, Chronic Obstructive
Product
fluticasone propionate, fluticasone propionate/salmeterol, fluticasone propionate/salmeterol/norflurane, norflurane, salmeterol
Collaborators
Not applicable
Study date(s)
June 2013 to August 2014
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2014-30-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website